ICHNO-ECHNO 2022 | Recent advances in targeted therapy for head and neck cancer

Kevin Harrington, FRCP, FRCR, FRSB, PhD, The Institute of Cancer Research and Royal Marsden Hospital, London, UK, discusses current options and recent advances in targeted therapies for head and neck cancer (HNC). For patients with locally advanced HNC, surgery is often a promising option and recent research has investigated the use of proton-beam radiotherapy for these patients. In patients with relapsed/metastatic HNC, there have been recent promising developments in the use of stereotactic-body radiotherapy for oligometastatic or oligo-progressive disease. Prof. Harrington also discusses the use of immunotherapy in this field. This interview took place at the joint International Congress on Innovative Approaches in Head and Neck Oncology and the European Congress on Head and Neck Oncology (ICHNO-ECHNO) 2022 hybrid meeting in Brussels, Belgium.